Vancouver, British Columbia–(Newsfile Corp. – January 16, 2023) – Norris Lithium Inc. (CSE: CHCK) (formerly Copper Ridge Exploration Inc.) (the “Company” or “Norris“) is pleased to announce that it has changed its name from Copper Ridge Exploration Inc. to Norris Lithium Inc. As part of the name change, the ticker symbol of the Company’s common shares on the Canadian Securities Exchange (the “CSE“) will also change from “COP” to “CHCK”. The common shares are expected to begin trading on the CSE under the new name and new ticker symbol with a new CUSIP number (CUSIP #65635M107/ISIN #CA65635M1077) at the market open on or around January 18, 2023. The name change reflects the Company’s strategic focus on the exploration and development of its lithium properties located in the Provinces of Ontario and Quebec.

About Norris Lithium Inc.

Norris is engaged in the acquisition, exploration, and development of mineral property assets in Canada. Norris recently acquired the Highway and Bus Lithium properties in the James Bay region of Quebec and holds the Solitude Lake Property located near the Savant Lake area in the Patricia Mining Division, Ontario. Norris’ objectives are to conduct exploration programs on its Solitude Lake Property and Quebec Lithium properties and to locate and develop other economic mineral properties of merit.

ON BEHALF OF THE BOARD OF DIRECTORS

R. Dale Ginn, Chief Executive Officer

For further information, please contact:
R. Dale Ginn
Email: dale@rsdcapital.com
Telephone: 204-794-5818

THE CANADIAN SECURITIES EXCHANGE HAS NOT APPROVED NOR DISAPPROVED OF THE CONTENT OF THIS PRESS RELEASE

This news release may contain certain “forward looking statements”. Forward-looking statements involve known and unknown risks, uncertainties, assumptions, and other factors that may cause the actual results, performance, or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Any forward-looking statement speaks only as of the date of this news release and, except as may be required by applicable securities laws, the Company disclaims any intent or obligation to update any forward-looking statement, whether as a result of new information, future events, or results or otherwise.

Leave a Reply

Your email address will not be published. Required fields are marked *

Sign Up for Our Newsletter

Get the latest investment ideas and strategies sent straight to your inbox.

You May Also Like

Rivalry Reports 192% Growth in Handle and 60% Growth in Revenue for Q2 2023, Projects Profitability in H1 2024

Bespoke Product, Creative Marketing Deliver Significant Year-Over-Year Growth, Cost Efficiencies, and Strong Revenue…

PsyBio Announces Closing of Second Tranche of Private Placement

Oxford, Ohio and Denver, Colorado–(Newsfile Corp. – January 13, 2023) – PsyBio…

nveric Biosciences Receives Notice of Allowance from USPTO for Novel Prodrug of Psilocin

Intellectual property describes composition of matter claims governing Enveric’s lead clinical candidate,…